BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26460295)

  • 1. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
    Feldman DR; Lorch A; Kramar A; Albany C; Einhorn LH; Giannatempo P; Necchi A; Flechon A; Boyle H; Chung P; Huddart RA; Bokemeyer C; Tryakin A; Sava T; Winquist EW; De Giorgi U; Aparicio J; Sweeney CJ; Cohn Cedermark G; Beyer J; Powles T
    J Clin Oncol; 2016 Feb; 34(4):345-51. PubMed ID: 26460295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
    Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
    Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.
    Oing C; Lorch A; Bokemeyer C; Honecker F; Beyer J; Berger LA; Oechsle K
    J Cancer Res Clin Oncol; 2015 May; 141(5):923-31. PubMed ID: 25395217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of brain metastases from germ cell tumors: a single center experience.
    Boyle HJ; Jouanneau E; Droz JP; Fléchon A
    Oncology; 2013; 85(1):21-6. PubMed ID: 23816811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
    Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
    Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
    Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
    Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
    ; Lorch A; Beyer J; Bascoul-Mollevi C; Kramar A; Einhorn LH; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin KA; Lotz JP; Germa Lluch JR; Powles T; Kollmannsberger CK
    J Clin Oncol; 2010 Nov; 28(33):4906-11. PubMed ID: 20956623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose Chemotherapy in Germ Cell Cancer Patients With Brain Metastases: Experience of an Expert Center.
    Delaye M; Benderra MA; Deforceville L; Larghero J; Parquet N; Culine S; Grazziotin-Soares D; Lotz JP
    Am J Clin Oncol; 2021 Aug; 44(8):423-428. PubMed ID: 34081032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
    J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
    Necchi A; Giannatempo P; Lo Vullo S; Farè E; Raggi D; Marongiu M; Scanagatta P; Duranti L; Giovannetti R; Girelli L; Nicolai N; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Gianni AM; Mariani L; Pastorino U; Salvioni R
    Clin Genitourin Cancer; 2015 Feb; 13(1):87-93.e1. PubMed ID: 25044148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
    Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
    J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastases in germ cell tumours: lessons learnt from a large retrospective study.
    Jamal-Hanjani M; Karpathakis A; Kwan A; Mazhar D; Ansell W; Shamash J; Harper P; Rudman S; Powles T; Chowdhury S
    BJU Int; 2013 Jul; 112(2):176-81. PubMed ID: 23795785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
    Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
    J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.